Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Raschi

Showing results (31-40 of 213) with videos related to

Pageof 22
Sort By:
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2025
Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors"Emanuel Raschi, Monia Donati, Francesco Salvo, et al.
Frontiers in Pharmacology|December 12, 2024
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guidelineMichele Fusaroli, Francesco Salvo, Charles Khouri, et al.
BMJ (Clinical Research Ed.)|November 3, 2022
Transparency and robustness of safety signalsCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Immunotherapy|January 11, 2023
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITYEmanuel Raschi, Francesca Comito, Francesco Massari, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 4, 2009
hERG-related drug toxicity and models for predicting hERG liability and QT prolongationEmanuel Raschi, Luisa Ceccarini, Fabrizio De Ponti, et al.
World Journal of Gastroenterology|November 30, 2016
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterologyGiovanni Dothel, Emanuel Raschi, Roberto Rimondini, et al.
Obesity Research & Clinical Practice|March 25, 2025
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?Angela Procacci, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Journal of the American College of Cardiology|May 7, 2016
Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting SystemsEmanuel Raschi, Francesco Salvo, Elisabetta Poluzzi, et al.
Pageof 22

Showing results (31-40 of 213) with videos related to

Sort By:
Pageof 22
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2025
Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors"Emanuel Raschi, Monia Donati, Francesco Salvo, et al.
Frontiers in Pharmacology|December 12, 2024
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guidelineMichele Fusaroli, Francesco Salvo, Charles Khouri, et al.
BMJ (Clinical Research Ed.)|November 3, 2022
Transparency and robustness of safety signalsCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Immunotherapy|January 11, 2023
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITYEmanuel Raschi, Francesca Comito, Francesco Massari, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 4, 2009
hERG-related drug toxicity and models for predicting hERG liability and QT prolongationEmanuel Raschi, Luisa Ceccarini, Fabrizio De Ponti, et al.
World Journal of Gastroenterology|November 30, 2016
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterologyGiovanni Dothel, Emanuel Raschi, Roberto Rimondini, et al.
Obesity Research & Clinical Practice|March 25, 2025
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?Angela Procacci, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Journal of the American College of Cardiology|May 7, 2016
Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting SystemsEmanuel Raschi, Francesco Salvo, Elisabetta Poluzzi, et al.
Pageof 22